Related Experiment Video

Updated: Jun 22, 2026

Real-Time Monitoring of Aurora kinase A Activation using Conformational FRET Biosensors in Live Cells
06:29

Real-Time Monitoring of Aurora kinase A Activation using Conformational FRET Biosensors in Live Cells

Published on: July 30, 2020

[Research progress on aurora kinase inhibitor MK-0457 in therapy for some hematological malignancies -- review]

Yi-Qiong Liang1, Bao-An Chen, Ya-Li Chen

  • 1Department of Hematology, Zhongda Hospital, Southeast University Clinical Medical College, Nanjing, Jiangsu Province, China.

Zhongguo Shi Yan Xue Ye Xue Za Zhi
|June 25, 2009
PubMed

Insights

MK-0457, an Aurora kinase inhibitor, halts cancer cell growth and induces apoptosis. This drug shows promise for treating refractory leukemias and myeloproliferative diseases, including those with specific mutations.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Aurora kinase inhibitor MK-0457 (VX-680) targets multiple kinases including Aurora A, B, C, BCR-ABL, FLT-3, and JAK-2.
  • It inhibits cell cycle progression and induces apoptosis in various human tumors.
  • MK-0457 demonstrates activity against wild-type and mutated BCR-ABL, including the T315I mutant, and inhibits FLT-3 and JAK-2 kinases.

Purpose of the Study:

  • To review the pharmacologic actions of MK-0457.
  • To discuss the clinical trial status and therapeutic applications of MK-0457.
  • To explore the potential of MK-0457 in treating hematological malignancies.

Main Methods:

  • Review of preclinical studies on MK-0457's mechanism of action.
  • Analysis of ongoing Phase II clinical trials involving MK-0457.
  • Evaluation of MK-0457's efficacy in various hematological cancer models.

Main Results:

  • MK-0457 effectively blocks cell cycle progression and induces apoptosis.
  • The inhibitor shows therapeutic effects in refractory Chronic Myeloid Leukemia (CML), Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph(+) ALL) with T315I mutation, relapsed refractory Acute Myeloid Leukemia (AML), and JAK-2 positive Myeloproliferative Diseases (MPD).
  • Activity against wild-type and mutated BCR-ABL, FLT-3, and JAK-2 has been confirmed.

Conclusions:

  • MK-0457 presents a promising therapeutic strategy for specific hematological malignancies.
  • Ongoing clinical trials are crucial for validating its efficacy and safety.
  • The drug's broad kinase inhibition profile offers potential for combination therapies.

More Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...